Patient preferences for inflammatory bowel disease treatment objectives

Digestive and Liver Disease

Volumn 49, Issue 2, 2017, Pages 152-156

  Casellas, Francesc ^a   Herrera de Guise, Claudia ^a   Robles, Virginia ^a   Navarro, Ester ^a   Borruel, Natalia ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Crohn's disease; Symptoms; Treatment expectations; Ulcerative colitis

Indexed keywords

CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; COLON SURGERY; COLONOSCOPY; CROHN DISEASE; DEFECATION URGENCY; DIARRHEA; FATIGUE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTOMY; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECTUM HEMORRHAGE; RELAPSE; TREATMENT OUTCOME; ULCERATIVE COLITIS; MIDDLE AGED; SPAIN;

ADULT; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SPAIN;

EID: 85000869301     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.09.009     Document Type: Article

References (24)

1. [1] Høivik, M.L., Moum, B., Solberg, I.C., et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN study. Gut 62 (2013), 368–375.
2. [2] Schölmerich, J., Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms. Alimentary Pharmacology & Therapeutics 24 (2006), 33–36.
3. [3] Casellas, F., Crohn's disease, feeling well or healthy?. Revista Española de Enfermedades Digestivas (Madrid) 102 (2010), 621–623.
4. [4] Sandborn, W.J., Hanauer, S., Van Assche, G., et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. Journal of Crohn's and Colitis 8 (2014), 927–935.
5. [5] Hindryckx, P., Baert, F., Hart, A., et al. Clinical trials in ulcerative colitis: a historical perspective. Journal of Crohn's and Colitis 9 (2015), 580–588.
6. [6] Williet, N., Sandborn, W.J., Peyrin-Biroulet, L., Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clinical Gastroenterology and Hepatology 12 (2014), 1246–1256 e6.
7. [7] Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. The American Journal of Gastroenterology 110 (2015), 1324–1338.
8. [8] Casellas, F., López-Vivancos, J., Casado, A., Malagelada, J.R., Factors affecting health related quality of life of patients with inflammatory bowel disease. Quality of Life Research 11 (2002), 775–781.
9. [9] Lönnfors, S., Vermeire, S., Greco, M., et al. IBD and health-related quality of life—discovering the true impact. Journal of Crohn's and Colitis 8 (2014), 1281–1286.
10. [10] Gray, J.R., Leung, E., Scales, J., Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Alimentary Pharmacology & Therapeutics 29 (2009), 1114–1120.
11. [11] Casellas, F., Vicens, D.G., Menéndez, S.R., et al. Patients’ perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis. Journal of Crohn's and Colitis 8 (2014), 1097–1107.
12. [12] Pacheco-Huergo, V., Viladrich, C., Pujol-Ribera, E., et al. Perception in chronic illnesses: linguistic validation of the revised Illness Perception Questionnaire and the Brief Illness Perception Questionnaire for a Spanish population. Atención Primaria 44 (2012), 280–287.
13. [13] Regueiro, M.D., McAnallen, S.E., Greer, J.B., et al. The inflammatory bowel disease specialty medical home: a new model of patient-centered care. Inflammatory Bowel Disease 22 (2016), 1971–1980.
14. [14] van Deen, W.K., Esrailian, E., Hommes, D.W., Value-based health care for inflammatory bowel diseases. Journal of Crohn's and Colitis 9 (2015), 421–427.
15. [15] Vuitton, L., Marteau, P., Sandborn, W.J., et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut, 2015.
16. [16] Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., et al. Development and validation of the Nancy histological index for UC. Gut, 2015.
17. [17] Carpio, D., López-Sanrromán, A., Calvet, X., et al. Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey. European Journal of Gastroenterology & Hepatology 28 (2016), 1056–1064.
18. [18] Schreiber, S., Panés, J., Louis, E., et al. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterology, 12, 2012, 108.
19. [19] Dudley-Brown, S., Baker, K., Ulcerative colitis from patients’ viewpoint: a review of two Internet surveys. Gastroenterology Nursing 35 (2012), 54–63.
20. [20] Randell, R.L., Long, M.D., Cook, S.F., et al. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflammatory Bowel Disease 20 (2014), 541–544.
21. [21] Horne, R., Chapman, S.C., Parham, R., et al. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One, 8, 2013, e80633.
22. [22] Vangeli, E., Bakhshi, S., Baker, A., et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Advances in Therapy 32 (2015), 983–1028.
23. [23] DiMuro, J., Thompson, K.D., Crate, D., et al. Tu1258 a tool for IBD patients to communicate their personalized goals of therapy to their providers. Gastroenterology 148:Suppl. 1 (2015), S839–S840.
24. [24] Siegel, C.A., Lofland, J.H., Naim, A., et al. Novel statistical approach to determine inflammatory bowel disease: patients’ perspectives on shared decision making. Patient 9 (2016), 79–89.